S&P 500   3,842.98 (-0.26%)
DOW   31,039.60 (-0.44%)
QQQ   325.24 (-0.34%)
AAPL   135.28 (-1.16%)
MSFT   227.32 (+1.04%)
FB   273.05 (+0.07%)
GOOGL   1,879.03 (-0.27%)
AMZN   3,285.75 (-0.64%)
TSLA   839.70 (-0.63%)
NVDA   547.12 (-1.37%)
BABA   257.09 (-1.12%)
CGC   33.32 (-0.72%)
GE   11.08 (+0.09%)
MU   84.58 (-0.51%)
AMD   95.40 (+4.23%)
NIO   58.68 (+0.58%)
T   28.65 (-0.62%)
F   11.59 (+0.52%)
ACB   10.29 (-7.88%)
BA   206.00 (-0.68%)
DIS   174.12 (+1.66%)
NFLX   581.69 (+0.32%)
GILD   66.45 (-0.79%)
S&P 500   3,842.98 (-0.26%)
DOW   31,039.60 (-0.44%)
QQQ   325.24 (-0.34%)
AAPL   135.28 (-1.16%)
MSFT   227.32 (+1.04%)
FB   273.05 (+0.07%)
GOOGL   1,879.03 (-0.27%)
AMZN   3,285.75 (-0.64%)
TSLA   839.70 (-0.63%)
NVDA   547.12 (-1.37%)
BABA   257.09 (-1.12%)
CGC   33.32 (-0.72%)
GE   11.08 (+0.09%)
MU   84.58 (-0.51%)
AMD   95.40 (+4.23%)
NIO   58.68 (+0.58%)
T   28.65 (-0.62%)
F   11.59 (+0.52%)
ACB   10.29 (-7.88%)
BA   206.00 (-0.68%)
DIS   174.12 (+1.66%)
NFLX   581.69 (+0.32%)
GILD   66.45 (-0.79%)
S&P 500   3,842.98 (-0.26%)
DOW   31,039.60 (-0.44%)
QQQ   325.24 (-0.34%)
AAPL   135.28 (-1.16%)
MSFT   227.32 (+1.04%)
FB   273.05 (+0.07%)
GOOGL   1,879.03 (-0.27%)
AMZN   3,285.75 (-0.64%)
TSLA   839.70 (-0.63%)
NVDA   547.12 (-1.37%)
BABA   257.09 (-1.12%)
CGC   33.32 (-0.72%)
GE   11.08 (+0.09%)
MU   84.58 (-0.51%)
AMD   95.40 (+4.23%)
NIO   58.68 (+0.58%)
T   28.65 (-0.62%)
F   11.59 (+0.52%)
ACB   10.29 (-7.88%)
BA   206.00 (-0.68%)
DIS   174.12 (+1.66%)
NFLX   581.69 (+0.32%)
GILD   66.45 (-0.79%)
S&P 500   3,842.98 (-0.26%)
DOW   31,039.60 (-0.44%)
QQQ   325.24 (-0.34%)
AAPL   135.28 (-1.16%)
MSFT   227.32 (+1.04%)
FB   273.05 (+0.07%)
GOOGL   1,879.03 (-0.27%)
AMZN   3,285.75 (-0.64%)
TSLA   839.70 (-0.63%)
NVDA   547.12 (-1.37%)
BABA   257.09 (-1.12%)
CGC   33.32 (-0.72%)
GE   11.08 (+0.09%)
MU   84.58 (-0.51%)
AMD   95.40 (+4.23%)
NIO   58.68 (+0.58%)
T   28.65 (-0.62%)
F   11.59 (+0.52%)
ACB   10.29 (-7.88%)
BA   206.00 (-0.68%)
DIS   174.12 (+1.66%)
NFLX   581.69 (+0.32%)
GILD   66.45 (-0.79%)
Log in
NASDAQ:LOGC

LogicBio Therapeutics Stock Forecast, Price & News

$8.46
-0.03 (-0.35 %)
(As of 01/22/2021 09:32 AM ET)
Add
Compare
Today's Range
$8.46
Now: $8.46
$8.46
50-Day Range
$6.95
MA: $7.97
$9.10
52-Week Range
$3.05
Now: $8.46
$11.60
Volume100 shs
Average Volume112,161 shs
Market Capitalization$268.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.34
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. It has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop new genome editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company was founded in 2014 and is headquartered in Lexington, Massachusetts.

MarketRank

Overall MarketRank

1.29 out of 5 stars

Medical Sector

706th out of 1,926 stocks

Biological Products, Except Diagnostic Industry

94th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LOGC
CUSIPN/A
CIKN/A
Phone617-245-0399
Employees41

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.84 per share

Profitability

Net Income$-40,130,000.00

Miscellaneous

Market Cap$268.91 million
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable
$8.46
-0.03 (-0.35 %)
(As of 01/22/2021 09:32 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LOGC News and Ratings via Email

Sign-up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











LogicBio Therapeutics (NASDAQ:LOGC) Frequently Asked Questions

How has LogicBio Therapeutics' stock been impacted by Coronavirus (COVID-19)?

LogicBio Therapeutics' stock was trading at $7.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LOGC shares have increased by 20.2% and is now trading at $8.46.
View which stocks have been most impacted by COVID-19
.

Is LogicBio Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LogicBio Therapeutics stock.
View analyst ratings for LogicBio Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than LogicBio Therapeutics?

Wall Street analysts have given LogicBio Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but LogicBio Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as LogicBio Therapeutics' CEO?

1,448 employees have rated LogicBio Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among LogicBio Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is LogicBio Therapeutics' next earnings date?

LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for LogicBio Therapeutics
.

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) announced its quarterly earnings results on Monday, November, 9th. The company reported ($0.34) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.41) by $0.07. The business earned $0.93 million during the quarter.
View LogicBio Therapeutics' earnings history
.

What price target have analysts set for LOGC?

2 Wall Street analysts have issued 12 month price targets for LogicBio Therapeutics' stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate LogicBio Therapeutics' share price to reach $20.00 in the next year. This suggests a possible upside of 136.4% from the stock's current price.
View analysts' price targets for LogicBio Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of LogicBio Therapeutics' key competitors?

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI).

Who are LogicBio Therapeutics' key executives?

LogicBio Therapeutics' management team includes the following people:
  • Mr. Frederic Chereau M.B.A., Pres, CEO & Director (Age 53, Pay $632.9k)
  • Dr. Mark A. Kay, Co-Founder & Independent Director (Age 62, Pay $102.5k)
  • Dr. Leszek Lisowski Ph.D., Co-Founder
  • Dr. Adi Barzel Ph.D., Co-Founder
  • Mr. Matthias B. Jaffe, Chief Financial Officer (Age 52)
  • Dr. Kyle Chiang Ph.D., Chief Operating Officer
  • Dr. Matthias Hebben, Global VP & Head of Technology Devel.
  • Ms. Mariana Nacht, Chief Scientific Officer
  • Dr. Daniel J. Gruskin M.D., Sr. VP & Head of Clinical Devel.

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an initial public offering on Friday, October 19th 2018. The company issued 5,800,000 shares at a price of $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager.

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $8.46.

How big of a company is LogicBio Therapeutics?

LogicBio Therapeutics has a market capitalization of $268.91 million. The company earns $-40,130,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. LogicBio Therapeutics employs 41 workers across the globe.

What is LogicBio Therapeutics' official website?

The official website for LogicBio Therapeutics is www.logicbio.com.

How can I contact LogicBio Therapeutics?

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The company can be reached via phone at 617-245-0399 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.